compounders sue fda over ending semaglutide shortage declaratory order resolved feb 21 2025 february Drug FDA declaration Wegovy shortage FDA declares end to Wegovy – Under The Hood, Novo Nordisk – Drug compounders sue US FDA

For the key secondary weight end point, the 12-mg group lost an average of 36.6 lb (16.8%) at 40 weeks, with no weight loss plateau observed through the end of the treatment period

Possible Side Effects & Cautions Like any medication, GLP-1s can cause side effectsmost commonly nausea, digestive changes, or mild fatigue

Sulphur burps are caused when the medication slows down your digestion

Market projections indicate a robust CAGR of 24.7% through 2034, signaling strong growth potential

A 2022 study published in JAMA Network Open found that people taking antidepressants experienced somewhat reduced weight loss with GLP-1 medications compared to those not taking antidepressants